Tomas Nyman

Tomas Nyman

Auto-generated profile, based on publicly available information

Tomas Nyman

Protein Science Facility, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Antiviral Research
Verified
Journal Article
Closed access
DADario Akaberi
Dario Akaberi
ABAmanda Båhlström
Amanda Båhlström
PCPraveen K. Chinthakindi
Praveen K. Chinthakindi
TNTomas Nyman
Tomas Nyman
ASAnja Sandström
Anja Sandström
JLJohan Lennerstrand
Johan Lennerstrand

10 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DMDominik Macak
Dominik Macak
SLShin-Yu Lee
Shin-Yu Lee
TNTomas Nyman
Tomas Nyman
HAHenry Ampah-Korsah
Henry Ampah-Korsah
ESEmilia Strandback
Emilia Strandback
HZHugo Zeberg
Hugo Zeberg
The enzyme AMPD1 is expressed in skeletal muscle and is involved in ATP production. All available Neandertal genomes carry a lysine-to-isoleucine substitution at position 287 in AMPD1. This variant, which occurs at an allele frequency of 0–8% outside Africa, was introduced to modern humans by gene flow from Neandertals. Here, we show that the catalytic activity of the purified Neandertal AMPD1 is ~25% lower than the ancestral enzyme, and when introduced in mice, it reduces AMPD activity in muscle extracts by ~80%. Among present-day Europeans, another AMPD1 variant encoding a stop codon occurs at an allele frequency of 9–14%. Individuals heterozygous for this variant are less likely to be top-performing athletes in various sports, but otherwise reduced AMPD1 activity is well tolerated in present-day humans. While being conserved among vertebrates, AMPD1 seems to have become less functionally important among Neandertals and modern humans.

2 December 2025 in Science Signaling
Verified
Journal Article
Closed access
MFMarlene Fritsche
Marlene Fritsche
GPGaia Picozzi
Gaia Picozzi
TNTomas Nyman
Tomas Nyman
HZHugo Zeberg
Hugo Zeberg
RÅRichard Ågren
Richard Ågren
G protein–coupled receptors (GPCRs) play key roles in neurodevelopment by regulating excitatory and inhibitory neuronal pathways. The G protein subunit Gα i1 is a downstream effector of inhibitory GPCR signaling, and the gene encoding it ( GNAI1 ) is abundantly expressed in the brain. Rare GNAI1 variants are linked to a severe neurodevelopmental disorder called GNAI1 syndrome, which is characterized by intellectual disability, a range of movement issues, and epilepsy. Here, we investigated the effect of five GNAI1 syndrome–associated missense variants on GPCR signaling. Predictions based on genetic biobank data and in silico modeling suggested that these variants were pathogenic. Compared with the wild-type protein, four Gα i1 variants (T48K, T48I, C224Y, and V332E) showed marked increases in dopamine potency at the dopamine D2 receptor (D2R) and increased constitutive G protein activity when expressed in Xenopus laevis oocytes. By contrast, the Gα i1 G40C variant was unresponsive to D2R activation. All Gα i1 variants displayed reduced GTP-γ-S binding rates and undetectable GTP hydrolysis, except for the T48I variant, which showed more rapid binding and hydrolysis. Thus, four GNAI1 syndrome variants caused a net gain-of-function effect on D2R signaling, and all studied variants disrupted GTP exchange. These biochemical effects may underlie GNAI1 syndrome, and GNAI1 mutations should therefore be considered when screening for rare neurodevelopmental disorders.